Influenza Vaccines Market Report 2025

The influenza vaccines market size has grown strongly in recent years. It will grow from $7.35 billion in 2024 to $7.9 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to pandemic preparedness, public health initiatives, vaccine effectiveness studies, healthcare professional recommendations, global influenza surveillance.

The influenza vaccines market size is expected to see strong growth in the next few years. It will grow to $11.02 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to climate and environmental factors, healthcare accessibility improvement, emergence of new influenza strains, innovation in adjuvants and delivery systems, rising healthcare expenditure. Major trends in the forecast period include wider use of mrna vaccine technology, pediatric immunization focus, seasonal influenza control measures, enhanced vaccination coverage in developing nations, tailored vaccination strategies.

The increasing incidence of seasonal influenza is expected to drive growth in the influenza vaccine market in the future. Seasonal influenza is a respiratory illness caused by influenza viruses that typically circulate during specific times of the year, usually in the colder months. This trend has emerged due to factors such as antigenic drift, population susceptibility, environmental influences, incomplete vaccine coverage, and the absence of universal vaccination. Influenza vaccines play a crucial role in reducing the incidence of seasonal influenza by providing immunization against the circulating strains of the virus. For instance, in November 2023, the Centers for Disease Control and Prevention (CDC), a U.S.-based government agency, reported that during the 2022-2023 flu season, there were approximately 31 million flu-related illnesses, 14 million flu-related medical visits, 360,000 flu-related hospitalizations, and 21,000 flu-related deaths. Thus, the rising incidence of seasonal influenza is propelling the growth of the influenza vaccine market.

The growth of the influenza vaccines market is further expected to be propelled by the increasing aging population. This demographic trend refers to a rising proportion of elderly individuals within a society, and this population segment utilizes influenza vaccines to mitigate the heightened susceptibility to severe complications and mortality associated with influenza infections. The aging process may lead to a weakening immune system, rendering individuals more vulnerable to infectious diseases such as influenza. According to the World Health Organization (WHO) in October 2022, the global population of people aged 60 years and older is projected to double by 2050, reaching 2.1 billion. Therefore, the expanding aging population is a significant driver of the influenza vaccines market.

An emerging trend in the influenza vaccine market is the adoption of technologically advanced vaccine production methods. Companies operating in this market are embracing innovative vaccine production technologies to maintain their competitive positions. For example, in January 2023, GlaxoSmithKline PLC introduced the Multiple Antigen Presenting System (MAPS) for vaccine development, offering an innovative approach to developing effective vaccines against bacteria and viruses. This technology is particularly useful for rapid vaccine development in response to epidemic or pandemic outbreaks.

Major companies in the influenza vaccine market are focusing on advanced product innovations, such as quadrivalent seasonal influenza vaccines, to enhance their respiratory vaccine portfolios and financial standings. A quadrivalent seasonal influenza vaccine is designed to provide protection against four different flu viruses, including two influenza A viruses and two influenza B viruses. In September 2023, Clover Biopharmaceuticals Ltd. launched AdimFlu-S (QIS), a quadrivalent seasonal influenza vaccine approved for use in individuals aged three years and older in China. The quadrivalent composition enhances the vaccine's effectiveness across different influenza B strains compared to trivalent options.

In November 2022, Pfizer Inc. entered into a partnership with BioNTech SE to develop an mRNA combination vaccine for influenza and COVID-19. This collaboration aims to initiate a phase I trial for a single-dose mRNA-based combination addressing both respiratory diseases. BioNTech SE, a Germany-based immunotherapy developer, is partnering with Pfizer Inc., a US-based pharmaceutical and biotechnology company, to advance this innovative approach to respiratory disease prevention.

Major companies operating in the influenza vaccines market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi-Aventis LLC., AstraZeneca PLC, GlaxoSmithKline plc., Serum Institute of India Private Limited, Takeda Pharmaceutical Company Limited, Moderna Inc., Viatris Inc., CSL Limited, Seqirus Inc., Daiichi Sankyo Company Limited, China National Pharmaceutical Group Corporation, Shanghai Fosun Pharmaceutical Group Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Shionogi & Co. Ltd., Liaoning Cheng Da Biotechnology Co. Ltd., Novavax AB, Sinovac Biotech Co. Ltd., Green Cross Corporation, Emergent BioSolutions Inc., Walvax Biotechnology Co. Ltd., Hualan Biological Engineering Inc., Valneva SE, Bharat Biotech International Limited, Vaxess Technologies Inc., Osivax, Gamma Vaccines Pty. Ltd.

North America was the largest region in the influenza vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the influenza vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the influenza vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Influenza vaccines, commonly known as flu vaccines, are designed to confer immunity against influenza viruses. These vaccines are quadrivalent, meaning they are formulated to provide protection against four different flu viruses, encompassing two influenza A viruses and two influenza B viruses.

The primary types of influenza vaccines are inactivated and live attenuated vaccines. Inactivated vaccines contain killed or inactivated microorganisms or viruses, stimulating an immune response without causing the disease. They are used to prevent infection and reduce the severity of illness caused by influenza viruses. Inactivated vaccines are available in both quadrivalent and trivalent formulations and are administered through injections and nasal sprays. These vaccines are suitable for both pediatric and adult populations and are distributed through various channels, including hospitals and pharmacies, government and institutional supply, and other distribution networks.

The influenza vaccines market research report is one of a series of new reports that provides influenza vaccines market statistics, including influenza vaccines industry global market size, regional shares, competitors with an influenza vaccines market share, detailed influenza vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the influenza vaccines industry. This influenza vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The influenza vaccines market consists of sales of recombinant influenza vaccines, high-dose influenza vaccines, cell-based influenza vaccines, and egg-based influenza vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.